Cargando…
Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms
Myeloproliferative neoplasms (MPNs) are clinically characterized by the chronic overproduction of differentiated peripheral blood cells and the gradual expansion of malignant intramedullary/extramedullary hematopoiesis. In MPNs mutations in JAK2 MPL or CALR are detected mutually exclusive in more th...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535894/ https://www.ncbi.nlm.nih.gov/pubmed/26484191 http://dx.doi.org/10.1016/j.gdata.2015.04.002 |
_version_ | 1782385667930587136 |
---|---|
author | Kameda, Takuro Shide, Kotaro Yamaji, Takumi Kamiunten, Ayako Sekine, Masaaki Hidaka, Tomonori Kubuki, Yoko Sashida, Goro Aoyama, Kazumasa Yoshimitsu, Makoto Abe, Hiroo Miike, Tadashi Iwakiri, Hisayoshi Tahara, Yoshihiro Yamamoto, Shojiro Hasuike, Satoru Nagata, Kenji Iwama, Atsushi Kitanaka, Akira Shimoda, Kazuya |
author_facet | Kameda, Takuro Shide, Kotaro Yamaji, Takumi Kamiunten, Ayako Sekine, Masaaki Hidaka, Tomonori Kubuki, Yoko Sashida, Goro Aoyama, Kazumasa Yoshimitsu, Makoto Abe, Hiroo Miike, Tadashi Iwakiri, Hisayoshi Tahara, Yoshihiro Yamamoto, Shojiro Hasuike, Satoru Nagata, Kenji Iwama, Atsushi Kitanaka, Akira Shimoda, Kazuya |
author_sort | Kameda, Takuro |
collection | PubMed |
description | Myeloproliferative neoplasms (MPNs) are clinically characterized by the chronic overproduction of differentiated peripheral blood cells and the gradual expansion of malignant intramedullary/extramedullary hematopoiesis. In MPNs mutations in JAK2 MPL or CALR are detected mutually exclusive in more than 90% of cases [1], [2]. Mutations in them lead to the abnormal activation of JAK/STAT signaling and the autonomous growth of differentiated cells therefore they are considered as “driver” gene mutations. In addition to the above driver gene mutations mutations in epigenetic regulators such as TET2 DNMT3A ASXL1 EZH2 or IDH1/2 are detected in about 5%–30% of cases respectively [3]. Mutations in TET2 DNMT3A EZH2 or IDH1/2 commonly confer the increased self-renewal capacity on normal hematopoietic stem cells (HSCs) but they do not lead to the autonomous growth of differentiated cells and only exhibit subtle clinical phenotypes [[4], [6], [7], [8],5]. It was unclear how mutations in such epigenetic regulators influenced abnormal HSCs with driver gene mutations how they influenced the disease phenotype or whether a single driver gene mutation was sufficient for the initiation of human MPNs. Therefore we focused on JAK2V617F and loss of TET2—the former as a representative of driver gene mutations and the latter as a representative of mutations in epigenetic regulators—and examined the influence of single or double mutations on HSCs (Lineage(−)Sca-1(+)c-Kit(+) cells (LSKs)) by functional analyses and microarray whole-genome expression analyses [9]. Gene expression profiling showed that the HSC fingerprint genes [10] was statistically equally enriched in TET2-knockdown-LSKs but negatively enriched in JAK2V617F–LSKs compared to that in wild-type-LSKs. Double-mutant-LSKs showed the same tendency as JAK2V617F–LSKs in terms of their HSC fingerprint genes but the expression of individual genes differed between the two groups. Among 245 HSC fingerprint genes 100 were more highly expressed in double-mutant-LSKs than in JAK2V617F–LSKs. These altered gene expressions might partly explain the mechanisms of initiation and progression of MPNs which was observed in the functional analyses [9]. Here we describe gene expression profiles deposited at the Gene Expression Omnibus (GEO) under the accession number GSE62302 including experimental methods and quality control analyses. |
format | Online Article Text |
id | pubmed-4535894 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-45358942015-10-19 Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms Kameda, Takuro Shide, Kotaro Yamaji, Takumi Kamiunten, Ayako Sekine, Masaaki Hidaka, Tomonori Kubuki, Yoko Sashida, Goro Aoyama, Kazumasa Yoshimitsu, Makoto Abe, Hiroo Miike, Tadashi Iwakiri, Hisayoshi Tahara, Yoshihiro Yamamoto, Shojiro Hasuike, Satoru Nagata, Kenji Iwama, Atsushi Kitanaka, Akira Shimoda, Kazuya Genom Data Data in Brief Article Myeloproliferative neoplasms (MPNs) are clinically characterized by the chronic overproduction of differentiated peripheral blood cells and the gradual expansion of malignant intramedullary/extramedullary hematopoiesis. In MPNs mutations in JAK2 MPL or CALR are detected mutually exclusive in more than 90% of cases [1], [2]. Mutations in them lead to the abnormal activation of JAK/STAT signaling and the autonomous growth of differentiated cells therefore they are considered as “driver” gene mutations. In addition to the above driver gene mutations mutations in epigenetic regulators such as TET2 DNMT3A ASXL1 EZH2 or IDH1/2 are detected in about 5%–30% of cases respectively [3]. Mutations in TET2 DNMT3A EZH2 or IDH1/2 commonly confer the increased self-renewal capacity on normal hematopoietic stem cells (HSCs) but they do not lead to the autonomous growth of differentiated cells and only exhibit subtle clinical phenotypes [[4], [6], [7], [8],5]. It was unclear how mutations in such epigenetic regulators influenced abnormal HSCs with driver gene mutations how they influenced the disease phenotype or whether a single driver gene mutation was sufficient for the initiation of human MPNs. Therefore we focused on JAK2V617F and loss of TET2—the former as a representative of driver gene mutations and the latter as a representative of mutations in epigenetic regulators—and examined the influence of single or double mutations on HSCs (Lineage(−)Sca-1(+)c-Kit(+) cells (LSKs)) by functional analyses and microarray whole-genome expression analyses [9]. Gene expression profiling showed that the HSC fingerprint genes [10] was statistically equally enriched in TET2-knockdown-LSKs but negatively enriched in JAK2V617F–LSKs compared to that in wild-type-LSKs. Double-mutant-LSKs showed the same tendency as JAK2V617F–LSKs in terms of their HSC fingerprint genes but the expression of individual genes differed between the two groups. Among 245 HSC fingerprint genes 100 were more highly expressed in double-mutant-LSKs than in JAK2V617F–LSKs. These altered gene expressions might partly explain the mechanisms of initiation and progression of MPNs which was observed in the functional analyses [9]. Here we describe gene expression profiles deposited at the Gene Expression Omnibus (GEO) under the accession number GSE62302 including experimental methods and quality control analyses. Elsevier 2015-04-09 /pmc/articles/PMC4535894/ /pubmed/26484191 http://dx.doi.org/10.1016/j.gdata.2015.04.002 Text en © 2015 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Data in Brief Article Kameda, Takuro Shide, Kotaro Yamaji, Takumi Kamiunten, Ayako Sekine, Masaaki Hidaka, Tomonori Kubuki, Yoko Sashida, Goro Aoyama, Kazumasa Yoshimitsu, Makoto Abe, Hiroo Miike, Tadashi Iwakiri, Hisayoshi Tahara, Yoshihiro Yamamoto, Shojiro Hasuike, Satoru Nagata, Kenji Iwama, Atsushi Kitanaka, Akira Shimoda, Kazuya Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms |
title | Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms |
title_full | Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms |
title_fullStr | Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms |
title_full_unstemmed | Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms |
title_short | Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms |
title_sort | gene expression profiling of loss of tet2 and/or jak2v617f mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms |
topic | Data in Brief Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535894/ https://www.ncbi.nlm.nih.gov/pubmed/26484191 http://dx.doi.org/10.1016/j.gdata.2015.04.002 |
work_keys_str_mv | AT kamedatakuro geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms AT shidekotaro geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms AT yamajitakumi geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms AT kamiuntenayako geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms AT sekinemasaaki geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms AT hidakatomonori geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms AT kubukiyoko geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms AT sashidagoro geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms AT aoyamakazumasa geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms AT yoshimitsumakoto geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms AT abehiroo geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms AT miiketadashi geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms AT iwakirihisayoshi geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms AT taharayoshihiro geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms AT yamamotoshojiro geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms AT hasuikesatoru geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms AT nagatakenji geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms AT iwamaatsushi geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms AT kitanakaakira geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms AT shimodakazuya geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms |